Protein kinase inhibitors (PKIs) are important therapeutic agents. As of 31 May 2021, the
United States Food and Drug Administration (USFDA) has approved 70 PKIs. Most of the …

Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

Constitutive activation of signal transducer and activator of transcription 3 (STAT3) is a
common feature in human non-small cell lung cancer (NSCLC). STAT3 plays an important …

It is now widely established that management of lung cancer is much more complex and
cannot be centered on the binary classification of small-cell versus non-small cell lung …

Lung cancer is one of main causes of cancer mortality and 83% of lung cancer cases are
classified as non-small cell lung cancer (NSCLC). Patients with NSCLC usually have a poor …

A series of novel hybrid pyrazolo [3, 4-d] pyramidine derivatives was designed and
chemically synthesized in useful yields. The synthesized compounds were structurally …

Lung cancer patients develop acquired resistance to tyrosine kinase inhibitors including
erlotinib (ERL) after few months of primary treatment. Evidently, new chemotherapy …

Abstract Background Mistletoe extract of Visucm album extract (VAE) contains many
biologically active components and has been reported to be not only a complementary and …

Tumors of the intestinal tract are among the most common tumor diseases in humans, but,
like many other tumor entities, show an unsatisfactory prognosis with a need for effective …

Tyrosine kinase inhibitors (TKIs) bring significant benefits for patients with cancers harboring
epidermal growth factor receptor (EGFR) mutations. However, after treatment for a certain …